Get the latest Science News and Discoveries

Recent FDA committee vote could speed multiple myeloma drug approval - EurekAlert


A U.S. Food and Drug Administration committee voted unanimously last month to approve a new clinical endpoint, minimal residual disease (MRD), when evaluating proposed drugs to treat multiple myeloma. The 12-0 vote by committee members was based primarily on an analysis spearheaded by C. Ola Landgren, M.D., Ph.D., first author of a new paper published yesterday in the journal Blood.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of FDA

FDA

Photo of EurekAlert

EurekAlert

Related news:

News photo

Neutrons open window to explore space glass - EurekAlert

News photo

Climate-smart marine spatial planning in Antarctica can be a model for the global ocean - EurekAlert

News photo

Flicker stimulation shines in clinical trial for epilepsy - EurekAlert